2. Pancreatic adenocarcinoma | ПРЕЦИЗИОННАЯ ОНКОЛОГИЯ

2. Pancreatic adenocarcinoma



You need to register on site.  Post will be published after being moderated


Pancreatic adenocarcinoma remains a highly lethal disease, with a 5-year survival rate of 6%. Surgical resection is the only curative option. Unfortunately, localized, potentially resectable disease often presents without overt signs or symptoms. Too often, patients are diagnosed late in their disease course with already metastasized cancers. As such, early detection of high-risk lesions remains the focus of considerable research. In this chapter, we will provide a comprehensive review of pancreatic adenocarcinoma, with a focus on recent progress in the field.


Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States. In 2013, an estimated 45,220 cases were diagnosed, with 38,460 deaths [1]. Although pancreatic cancer rarely presents before age 45, the overall incidence rises sharply thereafter. From 2006 to 2010, the SEER age-adjusted incidence rate of pancreatic adenocarcinoma was 12.2/100,000.

However, for individuals over age 65 the incidence rate is 69.4/100,000, and for individuals 80–84, the incidence rate is as high as 93.1/100,000 [2]. Hence, age is an important risk factor for the development of pancreatic cancer. Pancreatic cancer is slightly more prevalent among males than females (13.9 vs. 10.9 per 100,000) and blacks than whites (15.8 vs. 12.1 per 100,000) [2]. Despite several available treatment modalities (surgery, chemotherapy, radiation), the 5-year survival rate from pancreatic cancer remains dismal. The current rate of 6.5% is only slightly improved from the 2.4% documented between 1975 and 1977 [2].


The molecular biology of pancreatic adenocarcinoma is exceedingly complex, with an average of 63 genetically relevant mutations per tumor [3]. However, central to our understanding of carcinogenesis is the simpliified concept that pancreatic adenocarcinoma is the ?nal product of the progression of precursor lesions. These lesions are referred to as pancreatic intraepithelial neoplasia (PanIN) and progress through a series of sequential genetic alterations in the ductal epithelium (Fig. 2.1). The most well-studied effector of these alterations is the oncogenic KRAS gene, which was first associated with pancreatic cancer over two decades ago [4, 5]. Along with inactivation of the tumor suppressor genes CDKN2A, TP53, and SMAD4 (SMAD family member 4 gene, also known as deleted in pancreatic cancer 4, DPC4), the ductal epithelium is able to transform from minimally dysplastic PanIN grades 1A and 1B lesions to the more severely dysplastic grades 2 and 3 lesions. A recently published computational model based on data generated from the genome project estimates the time interval from initial mutation in the ductal epithelium (PanIN1) to the development of infiltrating carcinoma to be 11.7 years. Approximately 6.7 years is then required for a metastatic subclone to develop within the primary carcinoma, and a further 2.7 years to progress from metastatic dissemination to the patient’s death [6]. Unfortunately, the majority of pancreatic adenocarcinoma patients are diagnosed toward the end of this sequence.


Fig. 2.1. PanIN progression model, showing genetic alterations. PanIN, pancreatic intraepithelial neoplasia

The oncogenic KRAS mutation is present in nearly all pancreatic adenocarcinoma [4, 7]. Through transcription of an abnormal RAS protein that is constituently active, a number of downstream signaling pathways lead to aberrant cell proliferation. Similarly, inactivation of the tumor suppressor gene CDK2NA is present in more than 90% of pancreatic cancers [8]. These mutations lead to loss of the p16 protein, which plays an essential role in cell cycle regulation. TP53 mutations occur in approximately 75% of pancreatic cancer and lead to dysregulation of the cellular stress response [7, 9]. SMAD4/DPC4 mutations occur in approximately 55% of cases and lead to disruption of cell signaling in the transforming growth factor β (TGF-β) pathway [8, 10]. SMAD4/DPC4 mutations are associated with a poor prognosis in pancreatic adenocarcinoma [11]. Whereas KRAS is generally an earlier mutation, the loss of tumor suppressor genes occurs later in the sequence of dysplasia [12, 13].

Risk factors

Both inherited and environmental risk factors have been implicated in the pathogenesis of pancreatic adenocarcinoma. Hereditary susceptibility may account for up to 10% of pancreatic cancer cases and includes both genetic cancer syndromes [Lynch syndrome, familial atypical multiple mole melanoma syndrome (FAMMM), Peutz–Jeghers syndrome (PJS), hereditary breastovarian cancer syndrome (HBOC), familial adenomatous polyposis (FAP)] as well as familial pancreatic cancer [14]. Environmental risk factors such as smoking and alcohol as well as the co-morbid conditions of diabetes, obesity, and chronic pancreatitis have all been associated with an increased risk of pancreatic adenocarcinoma.

Table 2.1. Genetic syndromes associated with pancreatic adenocarcinoma

Syndrome Relative risk of pancreatic cancer Genes implicated
Familial adenomatous polyposis 4–6x APC
Lynch (formerly HNPCC) 8–9x MLH 1, MSH2, MSH6, PMS2
Hereditary breast–ovarian cancer 3.5–10x BRCA1, BRCA2, PALB2
Familial atypical multiple mole melanoma 13–22x P16/CDKN2A
Hereditary pancreatitis 25–60x PRSS1, SPINK1
Peutz–Jeghers syndrome 132x STK11/LKB1

Inherited risk factors

Several hereditary cancer syndromes have been associated with pancreatic adenocarcinoma (Table 2.1). Hereditary pancreatic cancer is characterized by a known genetic defect that increases the risk of pancreatic cancer. Familial pancreatic cancer (FPC), conversely, describes a family with at least two first-degree relatives with pancreatic cancer without an identifiable gene mutation or cancer syndrome [15].

Lynch syndrome, formerly known as HNPCC, arises from mutations in one of the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6, or PMS2. In addition to early-onset colorectal cancer, individuals with Lynch syndrome are predisposed to cancers of the pancreas, ovary, stomach, urinary tract, endometrium, and small bowel. Specifically, the risk of pancreatic cancer among individuals with Lynch syndrome is 1.31% up to age 50 and 3.7% up to age 70, which represents an 8.6-fold increase over the general U.S. population [16, 17].

Peutz–Jeghers syndrome (PJS) is an autosomal dominant hamartomatous polyposis syndrome caused by inherited mutations in the STK11/LKB1 gene on chromosome 19p13.3. Individuals with PJS have distinctive mucocutaneous pigmentation and are at increased risk for a number of GI malignancies, including colorectal cancer, gastric cancer, small bowel adenocarcinoma, and pancreatic cancer. The lifetime incidence of pancreatic cancer among patients with PJS has been estimated to be as high as 36% [18].

Familial atypical multiple mole melanoma (FAMMM) syndrome is an autosomal dominant condition associated with germline mutations in the p16/CDKN2A gene. Nevertheless, there is wide variability in the prevalence of the CDKN2A mutations among  patients  with FAMMM. Individuals with FAMMM have multiple dysplastic nevi that predispose them to malignant melanoma. In addition, these patients are at increased risk for pancreatic adenocarcinoma, lung and breast cancer, and sarcomas [16, 19]. Specifically, individuals with a germline p16 mutation have an approximately 17% lifetime risk of developing pancreatic cancer [20].

Hereditary breast–ovarian cancer (HBOC) syndrome is an autosomal dominant condition associated with germline mutations in the BCRCA1 and BRCA2 genes. Patients with BRCA1 or 2 mutations present with early-onset breast and ovarian cancer. Studies have also linked both of these mutations with an increased risk of pancreatic adenocarcinoma. Of the two mutations, the association with pancreas cancer is most robust for BRCA2, which carries an approximately 3.5 times increased risk over the general population [21]. In addition, 5.5% of Ashkenazi Jewish patients with resected PDAC have been shown to have founder mutations of BRCA1/2, compared to 1.1% of cancer-free controls [22]. As such, screening such high-risk groups for germline mutations in the absence of a family history of breast or ovarian cancer has been proposed.

Familial adenomatous polyposis (FAP) syndrome is an autosomal dominant condition associated with inherited mutations of the APC tumor suppressor gene. Individuals with FAP develop colon cancer at a very early age but are also at increased risk for duodenal, thyroid, hepatic, and pancreatic cancer. The relative risk of pancreatic adenocarcinoma among FAP patients and at-risk relatives has been estimated at 4.5 times that of the general population (RR, 4.45; 95% CI, 1.2– 11.4), with an absolute risk of 26.8/100,000 person years [23].

Hereditary pancreatitis (HP) is characterized by recurrent attacks of acute pancreatitis in childhood and adolescence with the eventual development of chronic pancreatitis over time. The autosomal dominant form of this disorder is associated with germline mutations of the PRSS1 gene, which encodes for cationic trypsinogen [24]. The risk of pancreatic cancer among patients with hereditary pancreatitis is significant, estimated at 19% at age 60 and 53% at age 75 [25]. This elevated risk may be secondary to inflammation, which has been shown to enhance cancer progression and amplify pathologic RAS activity [26, 27]. Among patients with hereditary pancreatitis, smoking and diabetes are preexisting risk factors that increase the risk of pancreatic cancer significantly [15, 28, 29].

Environmental risk factors

Several environmental factors predispose to pancreatic adenocarcinoma. Of these, cigarette smoking is the most well studied and perhaps the most significant, causing approximately 20–25% of all pancreatic cancers [30]. A pooled analysis of 12 case-control studies from the International Pancreatic Cancer Case-Control Consortium (PanC4) showed a twofold increased risk of pancreatic cancer among current smokers compared to never smokers (OR, 2.2; 95% CI, 1.7–2.8) [31]. While former smokers are also at increased risk (OR, 1.2; 95% CI, 1.0–1.3), this risk is attenuated to the level of normal smokers 20 years after quitting [31].

Another significant risk factor for pancreatic adenocarcinoma is diabetes mellitus. A recent meta-analysis of 36 cohort studies concluded that diabetes mellitus is associated with a 1.96-fold increase in pancreatic cancer (RR, 1.96; 95% CI, 1.66–2.27), controlling for several co-founders including alcohol consumption, BMI, and smoking status [32]. Furthermore, several studies have shown that the risk of pancreatic cancer is negatively correlated with the duration of diabetes.

Individuals with the shortest history of diabetes (<4 years) appear to have a 1.5-fold greater risk (OR, 1.5; 95% CI, 1.3–1.8) of developing pancreatic cancer than individuals with diabetes for 5 and 10 years, and a 2.1-fold greater risk than individuals with diabetes for more than 10 years (OR, 2.1; 95% CI, 1.9–2.3) [32, 33].

Elevated BMI has also been linked to an increased risk of pancreatic cancer, independent of the increased risk associated with diabetes [34–36]. Compared to individuals with a BMI between 18.5 and 24.9, those with a BMI >35 have a 1.55-fold increased risk of pancreatic cancer (OR, 1.55; 95% CI, 1.16–2.07) [36].

Centralized fat distribution, particularly in women, as well as early adulthood obesity have both been linked to an increased risk of pancreatic cancer, with the latter predisposing to earlier onset of disease [36, 37].

Alcohol increases one’s risk of pancreatic cancer, but only when consumed in large quantities. Mild to moderate alcohol consumption may even be protective. A meta-analysis of 21 casecontrol and 11 cohort studies reported a pooled relative risk of 1.22 (95% CI, 1.12–1.34) for those who consumed equal to or greater than three drinks per day, but only 0.92 (0.86–0.97) for those who consumed less than this amount [38]. This association appears to be independent of confounding chronic pancreatitis or smoking history.

Chronic pancreatitis is a well-known risk factor for pancreatic cancer. Although the risk is highest for patients with autosomal dominant hereditary pancreatitis (discussed above), patients with acquired chronic pancreatitis are also at risk. A pooled analysis of 10 case-control studies reported a nearly threefold increased risk of pancreatic cancer (OR, 2.71; 95% CI, 1.96–3.74) among patients diagnosed with pancreatitis more than 2 years before their cancer diagnosis [39]. However, the population attributable fraction was estimated at only 1.34%, suggesting that only a small portion of pancreatic cancer is secondary to chronic pancreatitis. Of note, via reverse causation, new-onset pancreatitis may also be a consequence of tumor-related duct obstruction, and thus a possible presentation of pancreatic cancer.

Finally, an association has also been reported between colonization of CagA-negative Helicobacter pylori infection and pancreatic cancer [40]. This association appears to be strongest among individuals with non-O blood types.

Clinical presentation

Patients with pancreatic adenocarcinoma present with nonSpecific complaints. Often, patients may describe vague abdominal discomfort and nausea in the setting of weight loss. When the location of the tumor is within the head of the pancreas (approximately 75% of cases), patients may present with jaundice from obstruction of the intra-pancreatic portion of the common bile duct [41]. A prospective study of 185 patients with newly diagnosed exocrine pancreatic cancer identified the most frequent presenting symptoms as asthenia (86%), anorexia (85%), weight loss (85%), abdominal pain (79%), and choluria (59%) [42]. Less frequently, pancreatic cancer may present as gastrointestinal bleeding from gastric varices secondary to splenic vein thrombosis [43]. Up to 80% of patients are either hyerperglycemic or frankly diabetic at the time of diagnosis, which has important implications for early detection and screening efforts [44].

As the natural history of pancreatic cancer progresses, patients are at risk for several more complications. In addition to cholestasis from biliary obstruction, patients may also develop acute pancreatitis from obstruction of the pancreatic duct. In one series, 18% of patients who underwent EUS-FNA following an episode of nonalcohol-, nongallstone-related acute pancreatitis were found to have pancreatic carcinoma [45]. Up to 10% of patients may develop gastric outlet obstruction or duodenal obstruction from tumor expansion [46]. There is a bidirectional interaction between pancreatic cancer and diabetes. If not present at diagnosis, diabetes may emerge either as a complication of tumor-induced insulin resistance and islet cell dysfunction or as chronic obstruction of the pancreatic duct with upstream glandular atrophy and loss of islet cells [47, 48]. Similarly, patients with pancreatic adenocarcinoma, preor postresection, may complain of steatorrhea from exocrine insuf?ciency and are also at increased risk for super?cial or deep venous thrombosis.

On physical exam, patients may have jaundice, lymphadenopathy, temporal wasting, hepatomegaly, or even ascites. Laboratory studies are similarly nonSpecific and may show anemia, hyperglycemia, or mild elevations in liver tests. Biomarkers such as CA 19-9 may also be elevated and are discussed below.

Serum tumor markers

The routine use of serum biomarkers is limited in the management of pancreatic adenocarcinoma. At present, carbohydrate antigen 19-9 (CA 19-9) is the only clinicially useful biomarker for this purpose. CA 19-9 is a sialylated Lewis (a) antigen normally absorbed onto the surface of erythrocytes [49]. Since CA 19-9 is also present on various mucins secreted by pancreatic adenocarcinoma cells, it has been used as a marker of prognosis and disease burden for pancreatic adenocarcinoma since the 1980s [49, 50]. An elevated CA 19-9 value of greater than 70 U/mL has a sensitivity and Specificity of 70% and 87%, respectively, for the diagnosis of pancreatic cancer [51]. With its low sensitivity and the fact that it can be elevated in benign pancreaticobiliary disease, CA 19-9 is not an effective screening test; however, it is useful as a marker of disease progression or recurrence following resection. Postresection CA 19-9 level also predicts overall survival among patients treated with adjuvant radiation. A large prospective study of 385 patients demonstrated a 72% reduction in the risk of death for patients with a CA 19-9 lower than 180 compared to those with a postoperative CA 19-9 level greater than 180 (HR, 2.53; p < 0.0001) [52]. Even patients with preoperative CA 19-9 levels as high as 900 can live as long as patients with normal values provided their postoperative CA 19-9 19-9 level falls within the normal range [53]. Other commonly used antigens such as CEA and CA 125, with sensitivities ranging from 30 to 60% and Specificities of approximately 80%, are less useful in the management of pancreatic adenocarcinoma, and not routinely used in clinical practice [54, 55]. In the future, newer technologies such as posttranscriptional gene regulation and next-generation gene sequencing will likely produce more promising, clinically relevant biomarkers to aid in early detection of pancreatic cancer and personalized treatment regimens [49].


Pancreatic ductal adenocarcinomas are highly infiltrative tumors. Grossly, these tumors are solid and ?rm; however, microscopically, their edges are poorly defined (Figs. 2.2 and 2.3). Often tongues of carcinoma extend beyond the main tumor [56, 57]. Invasion often occurs before the time of diagnosis along lymphatic and perineural spaces, as well as small veins.

The histological hallmark of pancreatic ducal adenocarcinoma is the associated intense desmoplastic reaction within the tumor (Fig. 2.4) [56]. This reaction is composed of fibroblasts, inflammatory cells, endothelial cells, and complex extracellular matrix, which combined produce an elevated interstitial ?uid pressure within the tumor [58]. Consequently, this elevated interstitial pressure induces vascular collapse and is thought to reduce perfusion to the tumor [58]. Reduced perfusion, in turn, has been implicated as a potential barrier to the adequate delivery of chemotherapeutic agents. On immunohistochemistry, pancreatic cancers may express CEA, cytokeratin, CA 19-9, B72.3 (TAG-72), CA 125, DUPAN2, as well as a number of mucins [56, 57].


Fig. 2.2. Gross image of resected pancreatic ductal adenocarcinoma. Tumor has practically replaced the entire head of pancreas and blocked the main pancreatic duct, while the common bile remained open


Fig. 2.3. Low-power image of infiltrating pancreatic ductal carcinoma in the background of parenchymal atrophy and prominent fibrosis (original magnification: x40)


Fig. 2.4. Pancreatic cancer typically consists of infiltrating angulated glands surrounded by desmoplastic stroma, which makes the tumor less accessible to chemotherapy. Pancreatic cancer is also prone to perineural invasion (left low corner) (original magnification: x200)


Pancreatic cancer is staged according to the American Joint Committee on Cancer (AJCC) tumor-node-metastasis classification (TNM) (Table 1.2) [59, 60]. The objective of the AJCC system is to generate a reproducible classification scheme based on which accurate predictions of prognosis and subsequent treatment recommendations can be generated. At present, this system is based on an assessment of resectability by helical CT scan. Whereas T1, T2, and T3 lesions are potentially resectable, T4 tumors, which involve the celiac axis or superior mesenteric artery, are not. Lesions that involve the superior mesenteric vein, splenic vein, and portal vein, provided they are patent, may be resectable depending on the expertise of the center and comfort of the surgeon with performing complex vascular reconstruction. A large-scale validation of the current system using the National Cancer Database (NCDB) found good 5-year survival discrimination by stage (p < 0.001). Stage 1A patients survived a median of 10 months, whereas stage IV patients had a median survival of 2.5 months [61].

A critique of the current system is the highly variable survival among resected patients of the same AJCC stage. To this end, a nomogram which incorporated additional factors such as tumor grade or degree of differentiation was proposed and was found to predict postresection survival more accurately than the AJCC system [62]. This nomogram was based on a prospective cohort of 555 consecutive patients and validated with a retrospective cohort of 424 patients [62]. More recent studies using the SEER database have proposed a TNMG classification after showing that for each AJCC stage, survival is significantly worse for high-grade vs. low-grade tumors [63, 64].


A multidisciplinary approach to care is essential in the management of pancreatic adenocarcinoma. Gastroenterologists, surgeons, oncologists, radiation oncologists, pathologists, primary care providers, and pain specialists must all play a coordinated role in prognostication, treatment, and palliation if necessary. Several studies have shown that such a coordinated effort often results in reinterpretation of data, changes in therapeutic recommendations, and improved survival [65, 66]. Management is discussed in detail in various chapters in the treatment section of this book.


Routine screening of pancreatic cancer in average-risk individuals is not recommended. The low incidence of pancreatic cancer combined with the lack of a low-cost screening modality makes such a strategy prohibitive. In contrast, screening to detect T1N0M0 disease and noninvasive precursor lesions such as PanIN and IPMN may be beneficial for those with an increased risk of pancreatic cancer. To date, several studies have looked at the utility of screening for pancreatic cancer in asymptomatic patients who have a significant family history and/or genetic predisposition for pancreatic cancer. A prospective study from the American Cancer of the Pancreas Consortium (CAPS) of 225 asymptomatic highrisk individuals identified 92 patients (42%) with  at least one pancreatic mass or dilated pancreatic duct by computed tomography (CT), magnetic resonance imaging (MRI), or endoscopic ultrasound (EUS). Of the 85 proven or suspected neoplasms, the vast majority were IPMNs (96%), with the remaining lesions reported as pancreatic endocrine tumors [67]. Not all screening programs have resulted in such a high yield, however. A similar 5-year prospective study of 76 high-risk individuals from families with familial pancreatic cancer from the National German Familial Pancreatic Cancer Registry (FaPaCa) found only three PanIN lesions and one IPMN using a similar EUS/MR/MRCP-based screening program [68] (Fig. 2.5).

Regardless, the most recent International CAPS Consortium guidelines recommend that appropriate candidates for screening are (1) firstdegree relatives (FDRs) of patients with PC from a familial PC kindred with at least two affected FDRs, (2) patients with PJS syndrome, or (3) p16, BRCA2, or HNPCC mutation carriers with at least one affected FDR [69]. Although EUS and/or MRI or magnetic resonance cholangiopancreatography (MRCP) were agreed upon as first-line screening modalities, no consensus was reached regarding appropriate age to start screening or stop surveillance, the appropriate interval for screening, or which screening abnormalities were concerning enough to warrant surgery [69].


Pancreatic adenocarcinoma remains a devastating and difficult-to-treat disease associated with a high mortality. Unfortunately, the majority of patients do not have resectable disease at the time of diagnosis. Although advances in surgical technology and chemotherapeutic regimens have resulted in incremental gains in survival, the current 5-year rate remains dismal at 6%. In the future, an improved understanding of the biology and genetics of this disease will hopefully provide a foundation for improvements in targeted and more effectivechemotherapeuticregimens.Furthermore, it is hoped that the identification and study of highrisk individuals will result in appropriate screening efforts and earlier detection of resectable lesions.


  1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11–30.
  2. Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, et al., editors. SEER cancer statistics review (CSR) 1975–2010. Bethesda: National Cancer Institute.
  3. Jones S, Zhang X, Parsons DW, Lin JC-H, Leary RJ, Angenendt P, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science. 2008;321(5897):1801–6.
  4. Di Magliano MP, Logsdon CD. Roles for KRAS in pancreatic tumor development and progression. Gastroenterology. 2013;144(6):1220–9.
  5. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell. 1988;53(4):549–54.
  6. Iacobuzio-Donahue CA. Genetic evolution of pancreatic cancer: lessons learnt from the pancreatic cancer genome sequencing project. Gut. 2012;61(7):1085–94.
  7. Rall CJ, Yan YX, Graeme-Cook F, Beauchamp R, Yandell DW, Povoski SP, et al. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Pancreas. 1996;12(1):10–7.
  8. Wood LD, Hruban RH. Pathology and molecular genetics of pancreatic neoplasms. Cancer J. 2012;18(6):492–501.
  9. Scarpa A, Capelli P, Mukai K, Zamboni G, Oda T, Iacono C, et al. Pancreatic adenocarcinomas frequently show p53 gene mutations. Am J Pathol. 1993; 142(5):1534.
  10. Hahn SA, Schutte M, Hoque AS, Moskaluk CA, da Costa LT, Rozenblum E, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science. 1996;271(5247):350–3.
  11. Blackford A, Serrano OK, Wolfgang CL, Parmigiani G, Jones S, Zhang X, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res. 2009;15(14):4674–9.
  12. Hidalgo M. Pancreatic cancer. N Engl J Med. 2010;362(17):1605–17.
  13. Feldmann G, Beaty R, Hruban RH, Maitra A. Molecular genetics of pancreatic intraepithelial neoplasia. J Hepatobiliary Pancreat Surg. 2007;14(3):224–32.
  14. Lucas AL, Chang MM, Lipsyc MD, Frucht H. The prevention and genetics of pancreatic cancer: a programmatic approach. In: Su GH, editor. Pancreatic cancer—methods and protocols. 2nd ed. New York: Springer; 2013.
  15. Solomon S, Das S, Brand R, Whitcomb DC. Inherited pancreatic cancer syndromes. Cancer J. 2012;18(6):485–91.
  16. Grover S, Syngal S. Hereditary pancreatic cancer. Gastroenterology. 2010;139(4):1076–80.
  17. Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA. 2009;302(16):1790–5.
  18. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz–Jeghers syndrome. Gastroenterology. 2000;119(6):1447–53.
  19. Lynch HT, Brand RE, Hogg D, Deters CA, Fusaro RM, Lynch JF, et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinomaprone families: the familial atypical multiple mole melanoma-pancreatic carcinoma syndrome. Cancer. 2002;94(1):84–96.
  20. Vasen HFA, Gruis NA, Frants RR, van der Velden PA, Hille ETM, Bergman W. Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a Specific 19 deletion of p16 (p16-Leiden). Int J Cancer. 2000;87(6):809–11.
  21. Consortium TBCL. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst. 1999;91(15):1310–6.
  22. Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol. 2009;27(3):433–8.
  23. Giardiello FM, Offerhaus GJ, Lee DH, Krush AJ, Tersmette AC, Booker SV, et al. Increased risk of thyroid and pancreatic carcinoma in familial adenomatous polyposis. Gut. 1993;34(10):1394–6.
  24. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet. 1996;14(2):141–5.
  25. Rebours V, Lйvy P, Ruszniewski P. An overview of hereditary pancreatitis. Dig Liver Dis. 2012;44(1): 8–15.
  26. Daniluk J, Liu Y, Deng D, Chu J, Huang H, Gaiser S, et al. An NF-?B pathway-mediated positive feedback loop ampli?es Ras activity to pathological levels in mice. J Clin Invest. 2012;122(4):1519–28.
  27. Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, et al. EMT and dissemination precede pancreatic tumor formation. Cell. 2012;148(1–2):349–61.
  28. Lowenfels AB, Maisonneuve P, Whitcomb DC, Lerch MM, DiMagno EP. Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis. JAMA. 2001;286(2):169–70.
  29. Rebours V, Boutron-Ruault M-C, Jooste V, Bouvier A-M, Hammel P, Ruszniewski P, et al. Mortality rate and risk factors in patients with hereditary pancreatitis: uniand multidimensional analyses. Am J Gastroenterol. 2009;104(9):2312–7.
  30. Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an update. Dig Dis. 2010;28(4–5):645–56.
  31. Bosetti C, Lucenteforte E, Silverman DT, Petersen G, Bracci PM, Ji BT, et al. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4). Ann Oncol. 2012;23(7):1880–8.
  32. Ben Q, Xu M, Ning X, Liu J, Hong S, Huang W, et al. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. Eur J Cancer. 2011;47(13):1928–37.
  33. Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M. Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer. 2005;92(11):2076–83.
  34. Aune D, Greenwood DC, Chan DSM, Vieira R, Vieira AR, Navarro Rosenblatt DA, et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response metaanalysis of prospective studies. Ann Oncol. 2012;23(4):843–52.
  35. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer. 2007;120(9):1993–8.
  36. Arslan AA, Helzlsouer KJ, Kooperberg C, Shu X-O, Steplowski E, Bueno-de-Mesquita HB, et al. Anthropometric measures, body mass index and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med. 2010;170(9):791–802.
  37. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, et al. Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. JAMA. 2009;301(24):2553–62.
  38. Tramacere I, Scotti L, Jenab M, Bagnardi V, Bellocco R, Rota M, et al. Alcohol drinking and pancreatic cancer risk: a meta-analysis of the dose-risk relation. Int J Cancer. 2010;126(6):1474–86.
  39. Duell EJ, Lucenteforte E, Olson SH, Bracci PM, Li D, Risch HA, et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2012;23(11):2964–70.
  40. Risch HA, Yu H, Lu L, Kidd MS. ABO blood group, Helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study. J Natl Cancer Inst. 2010;102(7):502–5.
  41. Brennan MF, Moccia RD, Klimstra D. Management of adenocarcinoma of the body and tail of the pancreas. Ann Surg. 1996;223(5):506–11; discussion 511–2.
  42. Porta M, Fabregat X, Malats N, Guarner L, Carrato A, de Miguel A, et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin Transl Oncol. 2005;7(5):189–97.
  43. Smith TA, Brand EJ. Pancreatic cancer presenting as bleeding gastric varices. J Clin Gastroenterol. 2001;32(5):444–7.
  44. Pannala R, Basu A, Petersen GM, Chari ST. Newonset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009;10(1):88–95.
  45. Tummala P, Tariq SH, Chibnall JT, Agarwal B. Clinical predictors of pancreatic carcinoma causing acute pancreatitis. Pancreas. 2013;42(1):108–13.
  46. Wong YT, Brams DM, Munson L, Sanders L, Heiss F, Chase M, et al. Gastric outlet obstruction secondary to pancreatic cancer: surgical vs endoscopic palliation. Surg Endosc. 2002;16(2):310–2.
  47. Park JW, Jang J-Y, Kim E-J, Kang MJ, Kwon W, Chang YR, et al. Effects of pancreatectomy on nutritional state, pancreatic function and quality of life. Br J Surg. 2013;100(8):1064–70.
  48. Muniraj T, Chari S. Diabetes and pancreatic cancer. Minerva Gastroenterol Dietol. 2012;58(4):331–45.
  49. Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107(1):15–22.
  50. Glenn J, Steinberg WM, Kurtzman SH, Steinberg SM, Sindelar WF. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas. J Clin Oncol. 1988;6(3):462–8.
  51. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989;110(9):704–9.
  52. Berger AC, Garcia Jr M, Hoffman JP, Regine WF, Abrams RA, Safran H, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol. 2008;26(36):5918–22.
  53. Turrini O, Schmidt CM, Moreno J, Parikh P, Matos JM, House MG, et al. Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy? J Gastrointest Surg. 2009;13(10):1791–7.
  54. Haglund C. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA. Br J Cancer. 1986;54(6):897–901.
  55. Benini L, Cavallini G, Zordan D, Rizzotti P, Rigo L, Brocco G, et al. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas. 1988;3(1):61–6.
  56. Hruban RH, Pitman MB, Klimstra DS, editors. Tumors of the pancreas. Atlas of tumor pathology. Washington, DC: American Registry of Pathology in collaboration with the Armed Forces Institute of Pathology; 2007.
  57. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008;3:157–88.
  58. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD, Hingorani SR. Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell. 2012;21(3):418–29.
  59. Edge S, Byrd DR, Compton CC, et al., editors. AJCC cancer staging manual. New York: Springer; 2010.
  60. Compton CC, Byrd DR, Garcia-Aguilar J, Kurtzman SH, Olawaiye A, Washington MK, editors. Exocrine and endocrine pancreas. AJCC cancer staging atlas. New York: Springer; 2012. p. 297–308.
  61. Bilimoria KY, Bentrem DJ, Ko CY, Ritchey J, Stewart AK, Winchester DP, et al. Validation of the 6th edition AJCC pancreatic cancer staging system: report from the National Cancer Database. Cancer. 2007;110(4):738–44.
  62. Ferrone CR, Kattan MW, Tomlinson JS, Thayer SP, Brennan MF, Warshaw AL. Validation of a postresection pancreatic adenocarcinoma nomogram for diseaseSpecific survival. J Clin Oncol. 2005;23(30):7529–35.
  63. Wasif N, Ko CY, Farrell J, Wainberg Z, Hines OJ, Reber H, et al. Impact of tumor grade on prognosis in pancreatic cancer: should we include grade in AJCC staging? Ann Surg Oncol. 2010;17(9):2312–20.
  64. Rochefort MM, Ankeny JS, Kadera BE, Donald GW, Isacoff W, Wainberg ZA, et al. Impact of tumor grade on pancreatic cancer prognosis: validation of a novel TNMG staging system. Ann Surg Oncol. 2013;20(13):4322–9.
  65. Pawlik TM, Laheru D, Hruban RH, Coleman J, Wolfgang CL, Campbell K, et al. Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol. 2008;15(8):2081–8.
  66. Katz MHG, Wang H, Fleming JB, Sun CC, Hwang RF, Wolff RA, et al. Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol. 2009;16(4):836–47.
  67. Canto MI, Hruban RH, Fishman EK, Kamel IR, Schulick R, Zhang Z, et al. Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology. 2012;142(4):796–804; quiz e14–5.
  68. Langer P, Kann PH, Fendrich V, Habbe N, Schneider M, Sina M, et al. Five years of prospective screening of high-risk individuals from families with familial pancreatic cancer. Gut. 2009;58(10):1410–8.
  69. Canto MI, Harinck F, Hruban RH, Offerhaus GJ, Poley J-W, Kamel I, et al. International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut. 2013;62(3):339–47.